Oncology is the branch of medicine that deals with the study, diagnosis and treatment of cancer and focuses on the management of cancer from diagnosis through to palliative care.
Cancer is a group of cells (usually derived from a single cell) that has lost its normal control mechanisms. Cancerous cells can develop from any tissue within any organ and can spread throughout the body (metastasise). Cancerous tissue can be divided into those of the blood and blood-forming tissue, and solid tumours, carcinomas or sarcomas, or described as breast cancer including metastatic breast cancer, HER2+, triple negative, gynaecological cancers such as ovarian and cervical, and genitourinary cancer such as prostate cancer.
Featured Learning Zones
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Related news and insights
Pfizer reports that following a preplanned efficacy and futility analysis, the independent Data Monitoring Committee (DMC) of the collaborative Phase III early breast cancer PALbociclib CoLlaborative Adjuvant Study (PALLAS) determined that the trial of Ibrance (palbociclib) plus standard adjuvant endocrine therapy is unlikely to show a statistically significant improvement in the primary endpoint of invasive disease-free survival (iDFS).
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Zercepac (trastuzumab), from Accord Healthcare, intended for the treatment of breast and gastric cancer.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Rozlytrek (entrectinib), from Roche, intended for the treatment of patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). Rozlytrek will be available as hard capsules (100 and 200 mg). Rozlytrek targets cells with constitutive activation of TRK proteins resulting from gene fusions and the proto-oncogene tyrosine-protein kinase ROS (ROS1).
The pathogenesis of cancer?associated disseminated intravascular coagulation (DIC) is complex and multifactorial. It could present as a spectrum ranging from clinically asymptomatic, but with laboratory markers of coagulation activation...